Answers are grounded in this paper and cite their sources.
Background: Liver dysfunction is one factor that affects the pharmacokinetics of voriconazole (VRCZ). Evaluation of liver function may thus be useful for setting the initial VRCZ dosage. Recently, the albumin-bilirubin (ALBI) score has been developed as a new model to assess liver function in liver disease. We explored the association between ALBI score and the incidence of plasma VRCZ concentrations ≥ 4 µg/mL during VRCZ administration in patients treated for hematological malignancies.
No takes yet. Share an insight, caveat, or question.
Miura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: